Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins
Overview
Authors
Affiliations
Solute carrier organic anion transporter family member 2A1 (OATP2A1, encoded by the SLCO2A1 gene), which was initially identified as prostaglandin transporter (PGT), is expressed ubiquitously in tissues and mediates the distribution of prostanoids, such as PGE, PGF, PGD and TxB. It is well known to play a key role in the metabolic clearance of prostaglandins, which are taken up into the cell by OATP2A1 and then oxidatively inactivated by 15-ketoprostaglandin dehydrogenase (encoded by HPGD); indeed, OATP2A1-mediated uptake is the rate-limiting step of PGE catabolism. Consequently, since OATP2A1 activity is required for termination of prostaglandin signaling via prostanoid receptors, its inhibition can enhance such signaling. On the other hand, OATP2A1 can also function as an organic anion exchanger, mediating efflux of prostaglandins in exchange for import of anions such as lactate, and in this context, it plays a role in the release of newly synthesized prostaglandins from cells. These different functions likely operate in different compartments within the cell. OATP2A1 is reported to function at cytoplasmic vesicle/organelle membranes. As a regulator of the levels of physiologically active prostaglandins, OATP2A1 is implicated in diverse physiological and pathophysiological processes in many organs. Recently, whole exome analysis has revealed that recessive mutations in SLCO2A1 cause refractory diseases in humans, including primary hypertrophic osteoarthropathy (PHO) and chronic non-specific ulcers in small intestine (CNSU). Here, we review and summarize recent information on the molecular functions of OATP2A1 and on its physiological and pathological significance.
Microcystin-RR is a biliary toxin selective for neonatal extrahepatic cholangiocytes.
Gupta K, Chen D, Wells R JHEP Rep. 2024; 7(1):101218.
PMID: 39687604 PMC: 11648759. DOI: 10.1016/j.jhepr.2024.101218.
Fatty Acid Metabolism Disruptions: A Subtle yet Critical Factor in Adverse Pregnancy Outcomes.
Cao X, Li M, Shao C, Shi J, Zhang T, Xie F Int J Biol Sci. 2024; 20(15):6018-6037.
PMID: 39664564 PMC: 11628336. DOI: 10.7150/ijbs.103404.
Mocking T, van Oostveen W, Veldhoven J, Minnee H, Fehres C, Whitehurst C Front Pharmacol. 2024; 15:1372109.
PMID: 38783936 PMC: 11111933. DOI: 10.3389/fphar.2024.1372109.
Gallego-Tamayo B, Santos-Aparicio A, Yago-Ibanez J, Munoz-Moreno L, Lucio-Cazana F, Fernandez-Martinez A Int J Mol Sci. 2024; 25(6).
PMID: 38542317 PMC: 10969968. DOI: 10.3390/ijms25063345.
Primary hypertrophic osteoarthropathy: genetics, clinical features and management.
Lu Q, Xu Y, Zhang Z, Li S, Zhang Z Front Endocrinol (Lausanne). 2023; 14:1235040.
PMID: 37705574 PMC: 10497106. DOI: 10.3389/fendo.2023.1235040.